SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate earnings, with the community debating whether strong results are already priced in or if the stock will skyrocket. Discussions include valuation concerns, potential for a stock split, and comparisons to other high-growth tech companies. Some traders are also pointing to possible catalysts beyond earnings, such as new government contracts and partnerships in the AI space.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss upcoming earnings and potential FDA-related news impacting its gene therapy, Elevidys. Community talking points revolve around revenue expectations, possible surprises in company guidance, and the potential for a short squeeze. Broader market sentiment and recent biotech sector activity are also influencing conversations around SRPT's valuation and future prospects.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the impact of increased AI spending and its potential to drive future growth, amidst concerns about current profitability. The community is split between those seeing a buying opportunity after the recent dip and others anticipating further declines, with some mentioning a possible partnership with OpenAI. Overall sentiment is mixed, with focus on Meta's AI strategy and comparing it to other tech giants.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

ENVB is trending as retail traders discuss its potential for a short squeeze, drawing comparisons to past squeezes like $BYND and $AMC. The community is focused on its low float and recent news, with some anticipating a significant price increase. Some traders are also discussing a reverse split.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as community members discuss the potential for the stock to reach $900 and beyond, driven by optimism around FDA approval of their oral treatment and strong positioning in the weight loss market, while also generating concerns around pricing following Trump's comments. Community members are weighing the potential impact of competition from other pharma companies and strategic moves within the sector.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant FDA update regarding its Huntington's disease treatment, AMT-130, which has sparked volatility and a mix of reactions. The community is discussing the unexpected regulatory shift and its potential impact on the drug's approval timeline. Community members are also considering the possibility of a buyout, speculating on the stock's long-term potential and potential courses of action.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as discussions revolve around its potential in the CML treatment landscape after positive data was presented. Some investors are optimistic about TERN-701's prospects, while others express concerns about the risks associated with Phase 1 stocks and potential dilutions. Amidst the TERN discussion, some traders are also eyeing ENVB for a potential short squeeze similar to BYND.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark is trending as investors digest the company's acquisition of Kenvue, with community discussions focusing on the deal's potential impact on KMB's stock value and dividend payouts. Some traders are considering short-term strategies around the CEO's appearance on Mad Money, while others are evaluating the long-term value and oversold conditions. Chatter also involves merger arbitrage strategies involving $KVUE.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as traders discuss its potential for a ZEC-like surge, with some highlighting its limited supply and comparing its potential to Bitcoin. Community members are actively speculating on price targets and whether DASH will benefit from renewed interest in privacy coins. There's also discussion about DASH's utility and integration with platforms like DoorDash.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

HTZ is trending as community members discuss its potential as a squeeze play, drawing comparisons to CVNA's past performance and highlighting high short interest. The recent partnership with Amazon to sell used cars is also fueling bullish sentiment and increased trading volume. Investors are watching for a potential breakout and positive earnings news as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire ZURICH and NESS ZIONA, Israel, Oct. 30...

NewCelX Ltd. operates as a Swiss biotechnology company. The private company is based in Kloten, Switzerland.

NewcelX Ltd.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.48
Prev Close	$7.29
Open	$5.80
Dividend Yield	0.00%
50-Day Moving Average	$18.71
Beta	0.42
Avg. Volume	88,507.26
PE Ratio	-4.20

52-Week High	$47.40
52-Week Low	$4.20
Market Capitalization	$31M
EPS (Annual)	-$2.63
Price to Book	10.74
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NCEL
NewcelX Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest NCEL News

NCELNewcelX Ltd.